Conditions: Urothelial Carcinoma Bladder Cancer
Keywords: sunitinib bladder neoplasm adjuvant treatment disease free survival cystectomy
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 7
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether sutent (sunitinib)is effective in preventing tumor recurrence in patients with high risk bladder cancer who have previously had chemotherapy and cystectomy (bladder removal).

A 4 month supply of the drug is given to patients beginning 2-3 months after bladder removal. The patients are followed up to 2 years.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Sunitinib
Intervention descriptions: intervention 1: Sunitinib 37.5 mg daily X 16 weeks

Protocol document: